Contact Information

Theodore Lowe, Ap #867-859
Sit Rd, Azusa New York

We Are Available 24/ 7. Call Now.

Blog Carnival: Cell and gene therapy industry to emerge
stronger post-COVID-19


Credit: Flickr

Finally, COVID-19 is no longer the only topic dominating the
news cycle, although it took several months before mainstream media
felt they could move away from covering a global pandemic that was
likely affecting every person on the planet. In some ways it was a
relief to know that the urgency had lessened and other news was
appropriate to report on again. Not that media have stopped
reporting on COVID-19 stories….

COVID-19 has presented the world with a common enemy. In most
countries, it has brought citizens together and we’ve witnessed
remarkable acts of kindness
and
charity
. Some companies have
thrived
in this pandemic world while many others have gone into

receivership
. The cell and gene therapy industry, being focused
on improving people’s health, has been in the thick of the battle
to find a vaccine and a treatment for ill patients. Will it emerge
victorious?

For five years now, Signals has been hosting a
blog carnival
. It was an experiment back in 2016 and I’m
pleased to say that the reception from you, our readers, has been
positive.

The blog carnival is an opportunity to hear from thought leaders
and bloggers about a topic that we believe is timely and relevant,
and will provoke different perspectives. We’ve covered
Right-to-Try
, the
10-year anniversary
of Yamanaka’s prize-winning research,
whether the cell and gene therapy industry “has
arrived
,” and more.

This year, I asked nine individuals and/or organizations to
think about how COVID-19 has presented both challenges and
opportunities for the regenerative medicine field
. I know
you will find their answers illuminating and thought-provoking
(they are thought leaders after all).

First-time contributors to the blog carnival Michael May,
President and CEO of CCRM, and Phil Vanek, Partner at Gamma
Biosciences, both offer an insightful overview of the industry
(here
and
here
). One perspective is more macro while the other could be
considered micro, yet they both touch on some of the same points
and even reference the same 19th century writer. Can you guess who?
You won’t want to miss what these industry leaders think about
the situation.

Brent McPherson, of World Courier, examines the topic from his
perspective as a
supply chain and logistics expert
. Read how the pandemic has
impacted those crucial areas of our industry and what we should be
doing post-pandemic.

The
California Institute for Regenerative Medicine
and the
Stem Cell Network
use their platforms to focus on promising
research coming from California and Canada. Blogger Tara Fernandez
also writes about research, in the area of
strokes
, and takeaways for COVID-19. Will our industry provide
a vaccine and/or treatment for the coronavirus? Read these blogs to
find out!

Susan Nichols, CEO of Falcon Therapeutics and Chairman of the
Board of Directors of the Rare Disease Innovations Institute,
contemplates how the first five months of staying home has affected
patients who are enrolled in, or awaiting, clinical trials. She
analyzes what we’ve learned so far and questions what that means
for therapy developers sponsoring clinical trials in the future.

Professor David Kent, University of York and a self-described
optimist,
searches for the silver lining
in this pandemic. Read his blog
to discover whether he finds it.

Last, but certainly not least, we learn what has been happening
in Australia. Will Australia produce a vaccine for its citizens?
And if it does, will it have the manufacturing infrastructure in
place to make it available? Chih Wei Teng, Chief Operating Officer
of CCRM Australia, titles his blog “In
search of a better tomorrow
.†No doubt, that is something we
all want – along with a quick return to our pre-pandemic
lives.


Credit: Flickr

Finally, COVID-19 is no longer the only topic dominating the
news cycle, although it took several months before mainstream media
felt they could move away from covering a global pandemic that was
likely affecting every person on the planet. In some ways it was a
relief to know that the urgency had lessened and other news was
appropriate to report on again. Not that media have stopped
reporting on COVID-19 stories….

COVID-19 has presented the world with a common enemy. In most
countries, it has brought citizens together and we’ve witnessed
remarkable acts of kindness
and
charity
. Some companies have
thrived
in this pandemic world while many others have gone into

receivership
. The cell and gene therapy industry, being focused
on improving people’s health, has been in the thick of the battle
to find a vaccine and a treatment for ill patients. Will it emerge
victorious?

For five years now, Signals has been hosting a
blog carnival
. It was an experiment back in 2016 and I’m
pleased to say that the reception from you, our readers, has been
positive.

The blog carnival is an opportunity to hear from thought leaders
and bloggers about a topic that we believe is timely and relevant,
and will provoke different perspectives. We’ve covered
Right-to-Try
, the
10-year anniversary
of Yamanaka’s prize-winning research,
whether the cell and gene therapy industry “has
arrived
,” and more.

This year, I asked nine individuals and/or organizations to
think about how COVID-19 has presented both challenges and
opportunities for the regenerative medicine field
. I know
you will find their answers illuminating and thought-provoking
(they are thought leaders after all).

First-time contributors to the blog carnival Michael May,
President and CEO of CCRM, and Phil Vanek, Partner at Gamma
Biosciences, both offer an insightful overview of the industry
(here
and
here
). One perspective is more macro while the other could be
considered micro, yet they both touch on some of the same points
and even reference the same 19th century writer. Can you guess who?
You won’t want to miss what these industry leaders think about
the situation.

Brent McPherson, of World Courier, examines the topic from his
perspective as a
supply chain and logistics expert
. Read how the pandemic has
impacted those crucial areas of our industry and what we should be
doing post-pandemic.

The
California Institute for Regenerative Medicine
and the
Stem Cell Network
use their platforms to focus on promising
research coming from California and Canada. Blogger Tara Fernandez
also writes about research, in the area of
strokes
, and takeaways for COVID-19. Will our industry provide
a vaccine and/or treatment for the coronavirus? Read these blogs to
find out!

Susan Nichols, CEO of Falcon Therapeutics and Chairman of the
Board of Directors of the Rare Disease Innovations Institute,
contemplates how the first five months of staying home has affected
patients who are enrolled in, or awaiting, clinical trials. She
analyzes what we’ve learned so far and questions what that means
for therapy developers sponsoring clinical trials in the future.

Professor David Kent, University of York and a self-described
optimist,
searches for the silver lining
in this pandemic. Read his blog
to discover whether he finds it.

Last, but certainly not least, we learn what has been happening
in Australia. Will Australia produce a vaccine for its citizens?
And if it does, will it have the manufacturing infrastructure in
place to make it available? Chih Wei Teng, Chief Operating Officer
of CCRM Australia, titles his blog “In
search of a better tomorrow
.†No doubt, that is something we
all want – along with a quick return to our pre-pandemic
lives.

Share:

administrator